Statins and renovascular disease in the elderly: a population-based cohort study
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
AIMS: More than 90% of cases of renovascular disease (RVD) are caused by atherosclerosis; thus patients with this condition are at high risk for vascular events. We examined the association of statins with prognosis in patients with RVD. METHODS AND RESULTS: We performed a population-based cohort study in 4040 patients with RVD older than 65 years using province-wide health data in Ontario, Canada. The primary outcome was time to first cardiorenal event, specifically myocardial infarction, stroke, heart failure, acute renal failure, dialysis or death; the primary analysis used a time-dependent covariate for statin exposure. Despite having a greater burden of cardiovascular and renal comorbidity, the risk of the primary outcome was significantly lower in statin users than in non-users [unadjusted hazard ratio (HR) 0.51, 95% confidence interval (CI) 0.47-0.57; P < 0.0001]. This association was materially unchanged after adjusting for demographic characteristics, cardiovascular risk factors, other comorbidities, measures of health-care utilization, screening, and concomitant medications (adjusted HR 0.51, 95% CI 0.46-0.57). An analysis using the same endpoint in a propensity-matched cohort without time-dependent statin exposure revealed a lower risk of the primary outcome in statin-treated patients but with a substantially more conservative point estimate (HR 0.82, 95% CI 0.71-0.95). CONCLUSION: These data suggest that statins are associated with improved prognosis in elderly patients with RVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“a recent population-based study showed that in patients >65 years of age with atherosclerotic renovascular disease, the risk of a major cardiorenal composite endpoint (MI, stroke, HF, acute renal failure, dialysis and death) was significantly lower in statin users than in nonusers.420”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [420]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Dyslipidaemias are very common in patients who have undergone heart, lung, liver, kidney, or allogenic haematopoietic stem cell transplantation, and predispose such patients to an increased risk of developing ASCVD and transplant arterial vasculopathy [497-501].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [500]
Experimental — accuracy not yet measuredIn the citing paper
“Dyslipidaemias are very common in patients who have undergone heart, lung, liver, kidney, or allogenic haematopoietic stem cell transplantation, and predispose such patients to an increased risk of developing ASCVD and transplant arterial vasculopathy [497-501].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [500]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revascularization versus Medical Therapy for Renal-Artery Stenosis
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905368 · Cited by 1,193
Austin, P. C., Daly, P. A., & Tu, J. V. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123839 · Cited by 525
Self-citationPrevalence of renovascular disease in the elderly: A population-based study
Hansen, K. J., Edwards, M. S., Craven, T. E., Cherr, G. S., Jackson, S. A., Appel, R. G., Burke, G. L., & Dean, R. H. (2002) · Journal of Vascular Surgery · doi:10.1067/mva.2002.127351 · Cited by 506
(2003) · PubMed · Cited by 490
Lee, D. S., Donovan, L., Austin, P. C., Gong, Y., Liu, P. P., Rouleau, J. L., & Tu, J. V. (2005) · Medical Care · doi:10.1097/00005650-200502000-00012 · Cited by 358 · cited 1×
“001 Coronary angiography (%) 294 (18) 162 (7) ,0.”
Self-citationKalra, P. A., Guo, H., Kausz, A. T., Gilbertson, D. T., Liu, J., Chen, S.-C., Ishani, A., Collins, A. J., & Foley, R. N. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00406.x · Cited by 334 · cited 1×
“Other comorbidities (%) Chronic liver disease 43 (3) 90 (4) 0.”
BackgroundTonelli, M., Moyé, L., Sacks, F. M., Cole, T., & Curhan, G. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068461.45784.2f · Cited by 306 · cited 2×
“001 Peptic ulcer disease 259 (15) 435 (18) 0.”
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04371206 · Cited by 275
Athyros, V. G., Mikhailidis, D. P., Liberopoulos, E. N., Kakafika, A. I., Karagiannis, A., Papageorgiou, A. A., Tziomalos, K., Ganotakis, E. S., & Elisaf, M. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl538 · Cited by 181
Angiotensin inhibition in renovascular disease: A population-based cohort study
Hackam, D. G., Duong-Hua, M. L., Mamdani, M., Li, P., Tobe, S. W., Spence, J. D., & Garg, A. X. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.05.013 · Cited by 143 · cited 3×
“001 Bone density testing (%) 104 (6) 85 (4) ,0.”
BackgroundSelf-citation
Research works printed but not linked: 1
- Levy, 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 10, 67
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Lipid-lowering therapy has never been tested in an RCT in patients affected by renovascular atherosclerosis; however, a recent nonrandomized population-based study showed that in patients older than 65 years of age with atherosclerotic renovascular disease raised the hypothesis that such treatment may yield cardiorena…”
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“65 years of age with atherosclerotic renovascular disease, the risk of a major cardiorenal composite endpoint (MI, stroke, HF, acute renal failure, dialysis and death) was significantly lower in statin users than in non-users.(420)”
Background
Metadata
- Authors
- Hackam, D. G., Wu, F., Li, P., Austin, P. C., Tobe, S. W., Mamdani, M. M., & Garg, A. X.
- Affiliations
- Western University (CA)
- University of Toronto (CA)
- St. Michael's Hospital (CA)
- Corresponding author
- Hackam, D. G.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-12-14
- Volume
- 32
- Issue
- 5
- Pages
- 598-610
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC3257309
- OpenAlex
- W2081426235
- Cited by
- 49
- References
- 29
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 5 · 2014: 4 · 2013: 4 · 2012: 1
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Physicians' Services Incorporated Foundation
- Canadian Institutes of Health Research (104702)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Keywords
- statins, renovascular disease, elderly patients, atherosclerosis, cardiovascular risk, renal outcomes, time-varying covariates, propensity score matching, prognosis
- MeSH terms
- Aged, Female, Heart Failure, Renal Dialysis, Humans, Kidney Failure, Chronic, Male, Myocardial Infarction, Ontario, Prognosis, Retrospective Studies, Risk Factors, Survival Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins and renovascular disease in the elderly: a population-based cohort study. https://app.cochat.ai/papers/10.1093/eurheartj/ehq452
- The paper
- Hackam, D. G., Wu, F., Li, P., Austin, P. C., Tobe, S. W., Mamdani, M. M., & Garg, A. X. (2011). Statins and renovascular disease in the elderly: a population-based cohort study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehq452
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.